Ageing research has finally reached human trials, and the money has arrived ahead of the evidence
For most of the past decade, the business of curing ageing was a story about money rather than medicine. That changed quietly this summer. On 9 June, a Boston company called Life Biosciences announced that it had dosed the first participant in a Phase 1 trial of ER-100, marking the first time a partial epigenetic reprogramming therapy had been given to a human being. The target was not immortality. It was open-angle glaucoma and a form of optic nerve damage called NAION, both leading causes of age-related, irreversible vision loss, and one of them with no approved treatment at all.
That is the shape of the industry now. Enormous ambitions, narrow first indications, and a wall of capital pressing against a very thin body of human evidence.
The money has already decided
The numbers are startling. Longevity biotech companies raised roughly $3.74bn across 49 financing events in the first quarter of 2026, according to an analysis by Longevity.Technology drawing on PitchBook data, up 56% on the same period a year earlier. That makes it one of the most active quarterly windows the sector has recorded.
The names behind it are familiar. Altos Labs launched in 2022 with $3bn, backed by Jeff Bezos among others, to pursue partial epigenetic reprogramming, a technique inspired by the Nobel-winning work of Shinya Yamanaka. Retro Biosciences was founded in 2021 on a single $180m cheque from Sam Altman, with no venture syndicate at all, and closed a new round in May 2026 at a $1.8bn pre-money valuation, with the stated goal of adding ten healthy years to human lifespan. Brian Armstrong’s NewLimit raised $130m in Series B financing for the same reprogramming thesis, and Elon Musk has described ageing at Davos as a very solvable problem.
Read the funding data closely, though, and the picture is less like a rising tide than a handful of very large waves. One analysis of pure-play longevity biotech notes that full-year 2025 looked far larger than 2024, at $1.45bn against $665m, but that the increase came from a few unusually large rounds rather than a broad rise in the number of companies being funded. Retro’s $1bn raise alone accounted for almost 95% of one quarter’s total. Strip out the outliers and the sector looks thinner than the headline suggests.
There is also a governance question the field rarely addresses. Retro’s founding capital came from one individual, and its most publicised scientific result came from a collaboration with a company that same individual runs. Concentration of that kind speeds decisions up and removes the drag of syndicate politics. It also leaves a clinical programme exposed to the attention span and the balance sheet of a single backer.
The money that is not venture capital
The billionaire framing obscures the largest institutional funder in the field, and it is not in California. Hevolution Foundation, established by royal decree in 2018 and funded by the Saudi government, aims to invest up to $1bn a year in ageing research and healthspan science. It has committed roughly $400m to geroscience, taken a $20m position in Aeovian Pharmaceuticals, and co-funded the $101m XPRIZE Healthspan competition. Its chief executive, Mehmood Khan, told the Global Healthspan Summit in Riyadh that the foundation had become “the second largest funder of geroscience and aging biology on the planet”.
That changes the character of the sector in a way most coverage misses. A sovereign-backed foundation is not chasing an exit. Its incentives run towards basic science, biomarker development and regulatory groundwork, the unglamorous work that venture money tends to skip. Hevolution has also been openly lobbying for a regulatory pathway that recognises pre-disease states, which is the bottleneck every company in this article eventually hits.
Why pharma is suddenly listening
The timing is not accidental. The pharmaceutical industry is walking into the largest revenue cliff in its history. The US market alone is projected to lose more than $230bn in revenue between 2025 and 2030 as patents on blockbuster drugs expire, with nearly 200 branded drugs, including 69 blockbusters, losing exclusivity in that window and between $200bn and $400bn of global revenue at risk. By this year, eight of the 13 largest pharmaceutical firms could see 30% or more of their revenue jeopardised.
Companies facing that arithmetic need pipelines, and they need them cheaply. Analysts have been explicit that acquiring early-stage biotechs with promising therapies is one of the main strategies for navigating a cliff of this size. A sector full of well-funded, pre-revenue ageing companies is exactly the sort of shopping aisle that creates.
Artificial intelligence supplies the second half of the story. Retro’s collaboration with OpenAI is the field’s most quoted example, with the companies reporting redesigned Yamanaka factor variants that produced more than 50 times higher expression of reprogramming markers than wild-type controls. It is a laboratory result, not a medicine, but it has done more for the sector’s narrative than any funding round.
The irony is that the people building these tools are the most sober about the odds. An Altos Labs machine-learning engineer recently pointed out that the number of new drugs developed each year is declining despite the advances in computing, and put the clinical acceptance rate at roughly 5% or less.
What is actually being tested
Three companies dominate the conversation, and their positions are very different.
Life Biosciences is furthest ahead. Its ER-100 uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4, to reset patterns of gene expression in older cells, and the Phase 1 trial evaluates safety and tolerability with additional endpoints assessing visual function. The therapy is delivered by injection into the eye and uses a doxycycline-controlled dual-vector system so that expression of the factors can be switched on and off, a design that addresses the field’s central fear. That fear is cancer. Reprogramming cells too far risks turning them into something that no longer behaves. David Sinclair, the Harvard geneticist who co-founded the company, said in its announcement that the dosing was “an important moment for Life Bio and for the field of aging biology”.
Retro is clinical, but not in reprogramming. Its lead candidate RTR242 is a small molecule designed to restore lysosomal function, the core of the cell’s waste recycling system, which loses efficiency with age and particularly in Alzheimer’s disease. The Phase 1 study is randomised, double-blind and placebo-controlled in healthy volunteers, run at an early-phase unit in Adelaide. Australia was not an accident. Early-phase safety trials are quicker and easier to get running there than in the United States, and the country’s research incentives make it a routine first stop for small companies that need clinical data before they need an American regulator. Where a trial is run has become a competitive variable in its own right, and it is one of the few levers a start-up can pull to buy time. Chief executive Joe Betts-LaCroix has said publicly that no dose-limiting toxicities have been seen, with early data expected around August 2026. At the time of writing, those results have not been published. Betts-LaCroix has been careful about what the milestone means, describing it in an interview with Core Memory as “a binary transition between being a discovery stage and a clinical stage company”. That is a statement about corporate status, not about efficacy, and the distinction matters.
Altos, the best funded of all, remains the quietest. One recent milestone tracker concluded that no trial registration or named candidate exists, and that its published work, including a substantial Cell paper on tissue changes across more than 40 tissues and 20 diseases, remains mechanism-level science. It has hired a chief medical officer, Joan Mannick, in a move widely read as preparation for clinical programmes.
None of these are trials of ageing. They are trials of eye disease, of dementia biology, of specific organ failure. That is not a retreat, it is the only route available. Regulators do not recognise ageing as an indication, and the field still lacks an agreed way to measure success. As the organisers of the XPRIZE Healthspan competition have put it, there is no universally accepted method of determining whether a therapy actually improves how people function, feel or survive, which they describe as the crisis at the centre of ageing research.
The gap between the pitch and the pipeline
The rhetorical register of this sector is its greatest liability. Bryan Johnson, who has spent millions on his own Blueprint protocol, announced in December that he intends to make humans immortal by 2039, calling it a reasonable target thanks to AI. He also conceded that his team do not currently know how this will be achieved, and that some therapies have the buggy problem of mistakenly causing cancer.
Set that against the Adelaide trial, where the achievement being celebrated is the absence of dose-limiting toxicity in healthy volunteers. Both things are called longevity. Only one of them is medicine.
Sober voices inside the field keep repeating the timeline. Biotech is a slow business in which fifteen years between initial research and clinical approval is entirely normal. Most reprogramming studies still involve mice or cell cultures, long-term safety in humans is unknown, and delivering reprogramming factors to specific tissues remains technically difficult. The mouse lifespan results that anchor every pitch deck have a long history of failing to translate.
There is also a market risk that has nothing to do with biology. If capital keeps concentrating in a small number of huge rounds while human data arrives slowly, valuations built on narrative will meet readouts built on reality.
The sector already has its cautionary precedent, and it is rarely named. Unity Biotechnology, the listed pioneer of senolytics, saw its shares nearly halve in 2023 when its lead candidate failed to match Regeneron’s Eylea in wet age-related macular degeneration. The same drug missed its primary endpoint in diabetic macular edema in March 2025, and the stock fell by roughly a third in a morning, to just over a dollar. As of early 2026, no senolytic drug had been approved by the FDA. The underlying science was not obviously wrong. The trials simply failed to deliver what the valuation had assumed, which is the precise risk now sitting under several billion dollars of private marks.
Some analysts already expect the fallout. One 2026 outlook predicts a wave of rescue acquisitions, with pharma buyers picking up scientifically sound but distressed assets at steep discounts as founders accept unfavourable terms.
Who gets the extra decade
The equity question is the one the sector answers least well. Longevity clinics have arrived long before longevity drugs, and they are not cheap. A review in the journal Aging found annual memberships commonly ranging from €10,000 to €50,000, with some executive packages exceeding €100,000. Pricing at that level, the authors wrote, makes such clinics “accessible only to wealthy elites, supporting a system of inequality in healthcare”, while the people most at risk of premature ageing come from the lowest socio-economic groups. Most of these services are not covered by insurance and have not been shown to extend lifespan.
In Asia the tension is sharper still. Japan, South Korea, Taiwan and Singapore are already classified as super-aged societies, Thailand and Malaysia will follow, and by 2030 one in four Asians will be over 60. Clinics across the region advertise regenerative and anti-ageing stem cell treatments, often without published outcome data or named medical directors, and researchers warn that this widens health inequality by selling unproven services to affluent clients while poorer groups lack basic preventive care. Singapore’s forthcoming licensing decisions over 2026 and 2027 will determine whether such clinics are regulated as medicine or as wellness, and a shakeout is likely if clinical standards apply.
Approval would not settle the access question, it would sharpen it. ER-100 is delivered as a controlled gene therapy by injection into the eye, and one-off gene therapies have consistently entered the market at prices in the hundreds of thousands of dollars per patient. If a reprogramming treatment for glaucoma arrives anywhere near that level, insurers and health ministries will be making a rationing decision rather than debating an abstraction, and they will be making it about a condition that affects tens of millions of people worldwide. Nobody in the sector has yet published a serious answer on pricing.
The argument the sector under-uses
The strongest case for putting public money into this field has almost nothing to do with billionaires. Ageing populations are a fiscal problem before they are a scientific one. Extra years of life have not automatically meant extra years of independence, and much of the additional time is spent managing chronic disease, drawing on pensions and absorbing unpaid care from families. Compressing that period of decline, even modestly, would move numbers that finance ministries actually track.
That is the distinction Hevolution presses when it separates healthspan from lifespan, and it is the version of the argument most likely to persuade a health system to pay. It is also the version the Silicon Valley end of the field deploys least often, preferring the language of defeating death. The rhetorical choice carries a cost. It invites the obvious response, which is that this is a luxury good for people who already have everything.
Verdict
Ageing will almost certainly become one of medicine’s biggest markets, because the diseases of ageing already are. Alzheimer’s, glaucoma, osteoarthritis, age-related hearing loss and blood disorders represent vast unmet need, and reprogramming and autophagy are credible mechanisms for attacking them upstream rather than managing their symptoms. If ER-100 or RTR242 produce clean safety data and interpretable biological signals, the capital now flooding the sector will look prescient.
The fantasy is the other claim, the one about defeating death itself. Nothing in the current pipeline supports it, and no regulator is being asked to approve it. Investors would do well to separate the two, because the market will eventually do so for them, and it will not be gentle about it.